Lebrikizumab

Published

dm+d

Unassigned

New Medicines

Moderate to severe atopic dermatitis in patients aged 12 years and older

Information

New molecular entity
Almirall
Eli Lilly

Development and Regulatory status

Phase II Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Humanised monoclonal antibody that binds to interleukin-13 thereby reducing type 2 inflammation
Atopic eczema is common and the prevalence is increasing. It is seen in 20% of children in developed countries and in developing countries the prevalence is heading towards this figure. In adults, population studies report an overall prevalence of 2-18%.
Moderate to severe atopic dermatitis in patients aged 12 years and older
Subcutaneous injection

Evidence based evaluations